amikacin has been researched along with Tuberculosis, Drug-Resistant in 87 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (6.90) | 18.2507 |
2000's | 11 (12.64) | 29.6817 |
2010's | 49 (56.32) | 24.3611 |
2020's | 21 (24.14) | 2.80 |
Authors | Studies |
---|---|
Moreno-Viguri, E; Pérez-Silanes, S; Santivañez-Veliz, M; Torres, E | 1 |
Camoin, L; Canaan, S; Cavalier, JF; Durand, T; Spilling, CD | 1 |
Barilar, I; Cirillo, DM; Farhat, MR; Freschi, L; Köser, CU; Miotto, P; Niemann, S; Spitaleri, A; Tahseen, S; Vargas, R | 1 |
Bhalla, M; Ciobanu, N; Conradie, F; Crudu, V; David, A; Denkinger, CM; Georghiou, SB; Kazi, M; Myneedu, VP; Penn-Nicholson, A; Rodrigues, C; Ruhwald, M; Schumacher, SG; Scott, L | 1 |
Guo, Y; Liu, H; Sha, W; Shen, H; Shen, X; Tan, G; Wu, X; Wu, Z; Yang, J; Yu, F | 1 |
Chaplin, M; Davies, GR; De Vos, M; Pillay, S; Schumacher, SG; Steingart, KR; Theron, G; Warren, R | 1 |
Bor, J; de Vos, M; Dolby, T; Horsburgh, CR; Jacobson, KR; Jenkins, HE; Leavitt, SV; Streicher, EM; Sy, KTL; Warren, RM | 1 |
Hsiao, HC; Jou, R; Wu, SH; Xiao, YX | 1 |
Brankin, A; Colman, RE; Georghiou, SB; Seifert, M; Suresh, A; Uplekar, S; Walker, TM | 1 |
Doustdar, F; Eslami, G; Ghalavand, Z; Habibnia, S; Karami-Zarandi, M; Kazemian, H; Zaker, S | 1 |
Catanzaro, A; Catanzaro, DG; Chiles, P; Ciobanu, N; Codreanu, A; Colman, RE; Cooney, CG; Crudu, V; Hillery, N; Holmberg, RC; Kukhtin, AV; Linger, Y; Norville, R; Rodwell, TC; Seifert, M; Syed, RR | 1 |
Anderson, K; Bian, A; Cox, H; Dheda, K; Pietersen, E; Shepherd, BE; Sterling, TR; van der Heijden, YF; Warren, RM | 1 |
Berge, I; Bogdanova, I; Freimane, L; Norvaiša, I; Ozere, I; Ranka, R; Sadovska, D; Vaivode, A; Vīksna, A | 1 |
Adeel, A; Ahmad, A; Ahmad, I; Aslam, H; Mushtaq, F; Raza, SM; Saleem, S | 1 |
Arnold, A; Cooke, GS; Dedicoat, M; Green, N; Harrison, TS; Kon, OM; Lipman, M; Loyse, A; Manalan, K | 1 |
De Maio, F; De Spirito, M; Delogu, G; Fimia, GM; Goletti, D; Maulucci, G; Palucci, I; Petrone, L; Piacentini, M; Romagnoli, A; Sali, M; Sanguinetti, M | 1 |
Budhathoki, C; Dooley, KE; Dowdy, DW; Farley, JE; Francis, HW; Han, HR; Hong, H | 1 |
Erber, J; Rothe, K; Schmid, RM; Schneider, J; Spinner, CD; Tschaikowsky, T; Weidlich, S | 1 |
Jafari, R; Moghim, S; Nasr Esfahani, B; Safari, M; Salehi, M | 1 |
Chen, J; Chen, X; He, G; Lin, S; Sun, F; Wang, S; Zhang, W | 1 |
Fox, GJ; Ho, J; Redwood, L; Velen, K; Wrohan, I | 1 |
Brar, MS; Brode, SK; Sabur, NF; Wu, L | 1 |
Ahmad, N; Atif, M; Ghafoor, A; Iqbal, Q; Khan, S; Latif, A; Saleem, F; Wahid, A | 1 |
Ahmad, K; Ahmad, Z; Ali, A; Rahat, S; Somayya, R | 1 |
Brouqui, P; Drancourt, M; Fournier, PE; Quenard, F | 1 |
Arnold, A; Chis Ster, I; Cooke, GS; Dedicoat, M; Harrison, TS; Kon, OM; Lipman, M; Loyse, A | 1 |
Akbar, HS; Atta, QM; Gul, F; Hassan, M; Jan, F; Muhammad, N; Wali, S | 1 |
Akkerman, OW; Bathoorn, E; de Lange, WCM; Lokate, M; Louka, C; Pournaras, S; Ravensbergen, SJ; Stienstra, Y; van der Werf, TS | 1 |
Ahmed, P; Gardezi, AH; Ikram, AI; Lalani, FK; Satti, ML; Zaman, G | 1 |
Bourkadi, JE; Chaoui, I; Chetioui, F; El Mzibri, M; Elmessaoudi, MD; Karimi, H; Laglaoui, A; Oudghiri, A; Zakham, F | 1 |
Draper, HR; Garcia-Prats, AJ; Hesseling, AC; McIlleron, HM; Norman, J; Rose, PC; Schaaf, HS; Seddon, JA | 1 |
Ihm, C; Kim, K; Park, J; Park, K; Shin, S; Shin, SY | 1 |
Frota, SMMC; Kritski, AL; Ruffino-Netto, A; Vasconcelos, KA | 1 |
Chaiprasert, A; Phunpruch, S; Prammananan, T; Sowajassatakul, A | 1 |
Ahmad, N; Ahuja, SD; Akkerman, OW; Alffenaar, JC; Anderson, LF; Baghaei, P; Bang, D; Barry, PM; Bastos, ML; Behera, D; Benedetti, A; Bisson, GP; Boeree, MJ; Bonnet, M; Brode, SK; Brust, JCM; Cai, Y; Caumes, E; Cegielski, JP; Centis, R; Chan, ED; Chan, PC; Chang, KC; Charles, M; Cirule, A; D'Ambrosio, L; Dalcolmo, MP; de Vries, G; Dheda, K; Esmail, A; Flood, J; Fox, GJ; Fréchet-Jachym, M; Fregona, G; Gayoso, R; Gegia, M; Gler, MT; Gu, S; Guglielmetti, L; Holtz, TH; Hughes, J; Isaakidis, P; Jarlsberg, L; Kempker, RR; Keshavjee, S; Khan, FA; Kipiani, M; Koenig, SP; Koh, WJ; Kritski, A; Kuksa, L; Kvasnovsky, CL; Kwak, N; Lan, Z; Lange, C; Laniado-Laborín, R; Lee, M; Leimane, V; Leung, CC; Leung, EC; Li, PZ; Lowenthal, P; Maciel, EL; Marks, SM; Mase, S; Mbuagbaw, L; Menzies, D; Migliori, GB; Milanov, V; Miller, AC; Mitnick, CD; Modongo, C; Mohr, E; Monedero, I; Nahid, P; Ndjeka, N; O'Donnell, MR; Padayatchi, N; Palmero, D; Pape, JW; Podewils, LJ; Reynolds, I; Riekstina, V; Robert, J; Rodriguez, M; Schnippel, K; Seaworth, B; Seung, KJ; Shim, TS; Singla, R; Smith, SE; Sotgiu, G; Sukhbaatar, G; Tabarsi, P; Tiberi, S; Trajman, A; Trieu, L; Udwadia, ZF; van der Werf, TS; Veziris, N; Viiklepp, P; Vilbrun, SC; Walsh, K; Westenhouse, J; Yew, WW; Yim, JJ; Zetola, NM; Zignol, M | 1 |
Akkerman, OW; Alffenaar, JC; Bolhuis, MS; Ghimire, S; Simbar, N; Sturkenboom, MGG | 1 |
Bisht, D; Faheem, M; Joshi, B; Khan, AU; Lata, M; Sharma, D; Shukla, S; Venkatesan, K | 1 |
Admasu, A; Berha, AB; Negash, Z; Sheth, AN; Shibeshi, W; Yimer, G | 1 |
Alagna, R; Besozzi, G; Castellotti, P; Cirillo, D; Codecasa, L; De Lorenzo, S; Ferrarese, M; Mazzola, E; Riccardi, N; Saderi, L; Sotgiu, G; Udwadia, Z; Viggiani, P | 1 |
Abdi, H; Arube, P; Dlamini, MG; Joloba, ML; Kamulegeya, R; Kasule, GW; Katabazi, FA; Kateete, DP; Khumalo, D; Kigozi, E; Lukoye, D; Musisi, K; Sebit, SI | 1 |
Choe, KH; Chung, GT; Hwang, SC; Jnawali, HN; Kim, H; Lee, YS; Park, YK; Ryoo, S | 1 |
Capocci, S; Cropley, I; Garcia Medina, R; Hopkins, S; Katiri, S; Lipman, M; Melchionda, V; Solamalai, A; Wyatt, H | 1 |
Gratz, J; Heysell, SK; Houpt, ER; Kibiki, GS; Kumburu, H; Mpagama, SG; Ndusilo, N; Peloquin, CA; Stroup, S | 1 |
Ajbani, K; Catanzaro, A; Caviedes, L; Coronel, J; Crudu, V; Desmond, E; Eisenach, K; Ganiats, TG; Garfein, RS; Groessl, EJ; Jackson, RL; Klages, S; Moore, D; Rodrigues, C; Rodwell, TC; Romancenco, E; Trollip, AP; Victor, T; Vineet, VP | 1 |
Kam, KM; Liu, M; Pang, Y; Wang, Y; Zhang, Z; Zhao, Y | 1 |
Kesenogile, B; Modongo, C; Ncube, R; Sirugo, G; Sobota, RS; Williams, SM; Zetola, NM | 1 |
Alland, D; Barry, CE; Chakravorty, S; Cho, EJ; Cho, SN; Kim, CT; Lee, J; Lee, JS; Roh, SS; Smith, LE; Via, LE | 1 |
Campbell, PJ; Posey, JE; Reeves, AZ; Willby, MJ | 1 |
Broda, A; Casali, N; Drobniewski, F; Gonzalo, X; Pardieu, C | 1 |
Augustynowicz-Kopeć, E; Bakuła, Z; Bielecki, J; Jagielski, T; Kamiński, M; Napiórkowska, A; Zwolska, Z | 1 |
Ader, F; Bouaziz, A; Catho, G; Dumitriescu, O; Pedone, C; Perpoint, T; Reix, P; Ronnaux-Baron, AS; Sénéchal, A; Valour, F | 1 |
Akkerman, OW; Alffenaar, JW; de Lange, WC; Dijkstra, JA; Kosterink, JG; Proost, JH; van Altena, R; van der Werf, TS | 1 |
Gumbo, T; Modongo, C; Pasipanodya, JG; Sirugo, G; Williams, SM; Zetola, NM | 1 |
Huang, H; Ke, Z; Liu, S; Mao, X; Shi, X; Tang, B; Wang, J | 1 |
Leufkens, HG; Mantel-Teeuwisse, AK; Mavhunga, F; Rennie, T; Ruswa, N; Sagwa, EL | 1 |
Sibbald, B | 1 |
Ajbani, K; Catanzaro, A; Georghiou, SB; Kambli, P; Nikam, C; Rodrigues, C; Rodwell, TC; Sadani, M; Shetty, A; Udwadia, Z | 1 |
Aubry, A; Brossier, F; Guindo, D; Pham, A; Reibel, F; Sougakoff, W; Veziris, N | 1 |
Cai, X; Deng, Y; Dong, H; Huan, S; Jing, H; Li, J; Li, Q; Li, X; Ou, X; Pang, Y; Su, B; Tan, Y; Xia, H; Zhang, J; Zhang, Z; Zhao, Y | 1 |
Forsman, LD; Hoffner, S; Hu, Y; Mansjö, M; Werngren, J; Xu, B; Zheng, R; Zheng, X | 1 |
Deshpande, D; Gumbo, T; Modongo, C; Pasipanodya, JG; Siyambalapitiyage Dona, CW; Srivastava, S | 1 |
Gumbo, T; Magazi, BT; Modongo, C; Pasipanodya, JG; Sirugo, G; Srivastava, S; Williams, SM; Zetola, NM | 1 |
Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS | 1 |
Blackmore, T; McNaughton, A; McNaughton, H | 1 |
Aubry, A; Bernard, C; Brossier, F; Jarlier, V; Pham, A; Sougakoff, W; Veziris, N | 1 |
Baghaei, P; Chitsaz, E; Farnia, P; Jalali, S; Kazempour, M; Mansouri, D; Masjedi, MR; Mirsaeidi, M; Tabarsi, P; Velayati, AA | 1 |
Braker, K; Cox, HS; Feuerriegel, S; Karimovich, HA; Niemann, S; Rüsch-Gerdes, S; Zarkua, N | 1 |
Li, C; Sugawara, I; Zhang, J | 1 |
Bzekalava, N; de Rijk, P; Fissette, K; Jugheli, L; Portaels, F; Rigouts, L | 1 |
Metchock, B; Posey, JE; Shinnick, TM; Sikes, RD; Zaunbrecher, MA | 1 |
Dauby, N; Payen, MC | 1 |
Böttger, EC; Chabula-Nxiweni, M; Coetzee, G; Gey van Pittius, NC; Hayes, C; Hoosain, EY; Sirgel, FA; Streicher, EM; Tait, M; Trollip, A; van Helden, PD; Victor, TC; Warren, RM | 1 |
Anthony, RM; Bergval, I; Bosman, M; Böttger, EC; Coetzee, G; Dheda, K; Gey van Pittius, NC; Streicher, EM; van Helden, PD; Victor, TC; Warren, RM | 1 |
Aarnoutse, RE; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; Kremer, K; ten Kate, MT; van Soolingen, D; Verbrugh, HA | 1 |
Catanzaro, A; Catanzaro, DG; Garfein, RS; Georghiou, SB; Magana, M; Rodwell, TC | 1 |
Kam, KM; Yip, CW | 1 |
Andrianasolo, D; Ramarokoto, H; Ramaroson, F; Rasolofo Razanamparany, V; Rasolonavalona, T; Ratsimba, L; Razafitsiarovana, I; Vincent, V | 1 |
Farnia, P; Khoshnood, K; Mansoori, SD; Masjedi, H; Masjedi, MR; Mirsaeidi, SM; Mohammadi, F; Pooramiri, MV; Rowhani-Rahbar, A; Tabarsi, P; Velayati, AA; Zahirifard, S | 1 |
Ovsiankina, ES; Panova, LV | 1 |
Carlos, L; da Silva, C; Müller, L | 1 |
Coker, RJ; Fisher, M; Tomlinson, DR | 1 |
Cropley, IM; Davidson, RN; Lovering, AM; Wade, P; Whitehead, TC | 1 |
Chen, M; Qian, H; Zhang, Y | 1 |
Bartsch, P; Corhay, JL; Gach, O; Lousberg, L | 1 |
Chan, CY; Chau, CH; Cheng, AF; Cheung, SW; Leung, CK; Wong, CF; Yew, WW | 1 |
Berning, SE; Cherry, TA; Iseman, MD | 1 |
de Jager, P; van Altena, R | 1 |
9 review(s) available for amikacin and Tuberculosis, Drug-Resistant
Article | Year |
---|---|
Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery.
Topics: Antitubercular Agents; Carboxylic Ester Hydrolases; Drug Design; Enzyme Inhibitors; Humans; Lactones; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Mycolic Acids; Organophosphorus Compounds; Orlistat; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2021 |
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
Topics: Adult; Amikacin; Antibiotics, Antitubercular; Drug Resistance, Bacterial; Ethionamide; Fluoroquinolones; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin; Sensitivity and Specificity; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2022 |
Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Humans; Ototoxicity; Tuberculosis, Multidrug-Resistant | 2021 |
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Carbapenems; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Recurrence; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.
Topics: Amikacin; Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Monte Carlo Method; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2018 |
[Children exposed to multidrug-resistant tuberculosis: How should we manage? Analysis of 46 child contacts and review of the literature].
Topics: Amikacin; Anti-Bacterial Agents; Child; Child, Preschool; Female; France; Humans; Infant; Latent Tuberculosis; Levofloxacin; Lost to Follow-Up; Male; Tuberculosis, Multidrug-Resistant | 2015 |
Diagnosis of Drug Resistance to Fluoroquinolones, Amikacin, Capreomycin, Kanamycin and Ethambutol with Genotype MTBDRsl Assay: a Meta-Analysis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Genotyping Techniques; Humans; Kanamycin; Kanamycin Resistance; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2015 |
The safety and tolerability of the second-line injectable antituberculosis drugs in children.
Topics: Adult; Amikacin; Animals; Antitubercular Agents; Capreomycin; Child; Drug Monitoring; Humans; Injections; Kanamycin; Risk Factors; Tuberculosis, Multidrug-Resistant | 2016 |
Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review.
Topics: Acetyltransferases; Amikacin; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Capreomycin; Drug Resistance, Multiple, Bacterial; Humans; Kanamycin; Methyltransferases; Mutation; Mycobacterium tuberculosis; Promoter Regions, Genetic; Tuberculosis, Multidrug-Resistant | 2012 |
6 trial(s) available for amikacin and Tuberculosis, Drug-Resistant
Article | Year |
---|---|
Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial.
Topics: Adolescent; Amikacin; Anesthetics, Local; Antitubercular Agents; Area Under Curve; Child; Cross-Over Studies; Double-Blind Method; Female; Humans; Injections, Intramuscular; Lidocaine; Male; Pain Measurement; Pain, Procedural; South Africa; Tuberculosis, Multidrug-Resistant | 2018 |
Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study.
Topics: Adult; Afghanistan; Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Iran; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2009 |
Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran.
Topics: Adolescent; Adult; Aged; Amikacin; Antitubercular Agents; Cycloserine; Drug Therapy, Combination; Female; Humans; Iran; Isoniazid; Male; Middle Aged; Ofloxacin; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2005 |
Multidrug-resistant tuberculosis.
Topics: Amikacin; Antitubercular Agents; Brazil; Drug Therapy, Combination; HIV Seronegativity; Humans; Quinolones; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 1996 |
[Bronchofiberscope and catheter intervention in treatment of multi-drug resistant pulmonary tuberculosis].
Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchoscopy; Catheterization, Peripheral; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ofloxacin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 1997 |
Serum pharmacokinetics of antimycobacterial drugs in patients with multidrug-resistant tuberculosis during therapy.
Topics: Adult; Amikacin; Antitubercular Agents; Female; Humans; Kanamycin; Male; Middle Aged; Tuberculosis, Multidrug-Resistant | 1999 |
72 other study(ies) available for amikacin and Tuberculosis, Drug-Resistant
Article | Year |
---|---|
Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.
Topics: Animals; Antitubercular Agents; Cell Line; Cyclic N-Oxides; Drug Resistance, Multiple, Bacterial; Latent Tuberculosis; Mice; Mycobacterium tuberculosis; Quinoxalines; Tuberculosis, Multidrug-Resistant | 2016 |
Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex.
Topics: Amikacin; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Epistasis, Genetic; Humans; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2021 |
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study.
Topics: Adult; Amikacin; Australia; Capreomycin; Cross-Sectional Studies; Drug Resistance, Bacterial; Ethionamide; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Prospective Studies; Rifampin; Sensitivity and Specificity; Sputum; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
Use of Whole-Genome Sequencing to Predict
Topics: Amikacin; Aminosalicylic Acid; Antitubercular Agents; China; Cycloserine; Drug Resistance; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Rifampin; Streptomycin; Tuberculosis, Multidrug-Resistant | 2022 |
Spatial heterogeneity of extensively drug resistant-tuberculosis in Western Cape Province, South Africa.
Topics: Amikacin; Antitubercular Agents; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; South Africa; Tuberculosis, Multidrug-Resistant | 2022 |
Development and Assessment of a Novel Whole-Gene-Based Targeted Next-Generation Sequencing Assay for Detecting the Susceptibility of Mycobacterium tuberculosis to 14 Drugs.
Topics: Amikacin; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; High-Throughput Nucleotide Sequencing; Humans; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Multidrug-Resistant | 2022 |
In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Genotype; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; World Health Organization | 2022 |
Molecular Characterization of Resistance to Second-Line Anti-Mycobacterial Drugs among Clinical Isolates of Multidrug-Resistant Mycobacterium tuberculosis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Humans; Iran; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |
Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Prospective Studies; Rifampin; Tuberculosis, Multidrug-Resistant | 2023 |
Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug-resistant tuberculosis in South Africa.
Topics: Adult; Amikacin; Aminosalicylic Acid; Antitubercular Agents; Ethionamide; Female; HIV Infections; Hospitals; Humans; Male; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Retrospective Studies; South Africa; Tuberculosis, Multidrug-Resistant | 2023 |
Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Latvia; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing | 2023 |
Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure.
Topics: Amikacin; Antitubercular Agents; Humans; Isoniazid; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; Verapamil | 2023 |
A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK.
Topics: Amikacin; Antitubercular Agents; Costs and Cost Analysis; Diarylquinolines; Humans; Retrospective Studies; Tuberculosis, Multidrug-Resistant; United Kingdom | 2020 |
Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against
Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Autophagy; Cystamine; Cysteamine; DNA Replication; Drug Synergism; Granuloma; GTP-Binding Proteins; Humans; Macrophages; Mycobacterium tuberculosis; Protein Glutamine gamma Glutamyltransferase 2; THP-1 Cells; Transglutaminases; Tuberculosis, Multidrug-Resistant | 2019 |
Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa.
Topics: Adolescent; Adult; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Antitubercular Agents; Audiometry; Auditory Threshold; Cross-Sectional Studies; Female; Hearing Loss; HIV Infections; Humans; Hypoalbuminemia; Kanamycin; Male; Middle Aged; Ototoxicity; Prevalence; Renal Insufficiency; South Africa; Thinness; Tuberculosis, Multidrug-Resistant; Young Adult | 2020 |
Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report.
Topics: Amikacin; Antitubercular Agents; Diarylquinolines; Drug Resistance, Bacterial; Female; Humans; Imipenem; Levofloxacin; Macrolides; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Skin; Skin Diseases, Bacterial; Soft Tissue Infections; Soft Tissue Injuries; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Vietnam; Young Adult | 2020 |
Sequence-based detection of first-line and second-line drugs resistance-associated mutations in Mycobacterium tuberculosis isolates in Isfahan, Iran.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Antitubercular Agents; Capreomycin; DNA Mutational Analysis; Drug Resistance, Multiple, Bacterial; Ethambutol; Female; Genetic Variation; Genotype; Humans; Iran; Isoniazid; Kanamycin; Male; Middle Aged; Mycobacterium tuberculosis; Ofloxacin; Rifampin; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant | 2020 |
Analysis of Serial Multidrug-Resistant Tuberculosis Strains Causing Treatment Failure and Within-Host Evolution by Whole-Genome Sequencing.
Topics: Amikacin; Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Retrospective Studies; Treatment Failure; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing | 2020 |
Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB).
Topics: Adult; Amikacin; Antitubercular Agents; Cohort Studies; Drug Monitoring; Female; Hearing Loss; Humans; Male; Retrospective Studies; Tinnitus; Treatment Outcome; Tuberculosis, Multidrug-Resistant; World Health Organization | 2021 |
Effectiveness of Shorter Treatment Regimen in Multidrug-Resistant Tuberculosis Patients in Pakistan: A Multicenter Retrospective Record Review.
Topics: Adult; Amikacin; Antitubercular Agents; Clofazimine; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Female; Humans; Isoniazid; Lost to Follow-Up; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pakistan; Pyrazinamide; Retrospective Studies; Survival Analysis; Treatment Failure; Tuberculosis, Multidrug-Resistant | 2021 |
Analysis of rrs gene mutations in amikacin resistant clinical isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Base Sequence; DNA Mutational Analysis; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Pakistan; RNA, Ribosomal, 16S; Tuberculosis, Multidrug-Resistant | 2017 |
Role of second-line injectable antituberculosis drugs in the treatment of MDR/XDR tuberculosis.
Topics: Amikacin; Antitubercular Agents; Follow-Up Studies; Humans; Injections, Intramuscular; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2017 |
Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.
Topics: Acute Kidney Injury; Adult; Amikacin; Antitubercular Agents; Capreomycin; Drug Therapy, Combination; Female; Hearing Loss; Humans; Hypokalemia; Male; Mycobacterium tuberculosis; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
Electrolytes imbalance caused by amikacin in patients receiving multi drug resistance- tuberculosis treatment at Hazara region Kpk, Pakistan.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Hypokalemia; Male; Middle Aged; Pakistan; Potassium; Risk Factors; Tuberculosis, Multidrug-Resistant; Water-Electrolyte Imbalance; Young Adult | 2017 |
Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug-Resistant Tuberculosis.
Topics: Adult; Amikacin; Carbapenem-Resistant Enterobacteriaceae; Clofazimine; Drug Monitoring; Humans; Linezolid; Male; Moxifloxacin; Netherlands; Prevalence; Prothionamide; Refugees; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Multidrug-Resistant | 2018 |
Evaluation of Nitrate Reductase Assay for Early Detection of Multi and Extensively Drug Resistance Tuberculosis in our Setup.
Topics: Amikacin; Antitubercular Agents; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Early Diagnosis; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitrate Reductase; Predictive Value of Tests; Rifampin; Sensitivity and Specificity; Sputum; Tuberculosis, Multidrug-Resistant | 2018 |
Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
Topics: Amikacin; Antitubercular Agents; Base Sequence; Capreomycin; DNA Mutational Analysis; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Gene Frequency; Humans; Kanamycin; Microbial Sensitivity Tests; Morocco; Mutation; Mycobacterium tuberculosis; Ofloxacin; Prevalence; Tuberculosis, Multidrug-Resistant | 2018 |
Determining Genotypic Drug Resistance by Ion Semiconductor Sequencing With the Ion AmpliSeq™ TB Panel in Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Genotype; Humans; Kanamycin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Phenotype; Polymerase Chain Reaction; Semiconductors; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant | 2018 |
Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Aged; Amikacin; Antitubercular Agents; Audiometry, Pure-Tone; Auditory Threshold; Early Diagnosis; Female; Hearing; Hearing Disorders; Hearing Tests; Humans; Longitudinal Studies; Male; Middle Aged; Otoacoustic Emissions, Spontaneous; Prospective Studies; Reproducibility of Results; Statistics as Topic; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2018 |
Overexpression of eis without a mutation in promoter region of amikacin- and kanamycin-resistant Mycobacterium tuberculosis clinical strain.
Topics: Acetyltransferases; Amikacin; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Gene Expression; Humans; Kanamycin; Microbial Sensitivity Tests; Mutation; Promoter Regions, Genetic; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant | 2018 |
Role of M.tuberculosis protein Rv2005c in the aminoglycosides resistance.
Topics: Amikacin; Aminoglycosides; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Gene Expression Regulation, Bacterial; Kanamycin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Protein Interaction Maps; Tuberculosis, Multidrug-Resistant | 2019 |
Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Amikacin; Antitubercular Agents; Capreomycin; Child; Child, Preschool; Creatinine; Ethiopia; Female; HIV Infections; Humans; Kanamycin; Kidney Diseases; Male; Middle Aged; Ototoxicity; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult | 2019 |
Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres.
Topics: Adult; Amikacin; Antitubercular Agents; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Female; Humans; Italy; Laboratories, Hospital; Linezolid; Male; Meropenem; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2019 |
Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016).
Topics: Amikacin; Antitubercular Agents; Capreomycin; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Eswatini; Fluoroquinolones; Gene Frequency; Humans; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Sequence Analysis, DNA; Somalia; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Uganda | 2019 |
Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea.
Topics: Acetyltransferases; Amidohydrolases; Amikacin; Antigens, Bacterial; Bacterial Proteins; Capreomycin; Catalase; DNA Gyrase; DNA Primers; DNA-Directed RNA Polymerases; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambutol; Fluoroquinolones; Genetic Loci; Humans; Isoniazid; Kanamycin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Oxidoreductases; Pentosyltransferases; Polymerase Chain Reaction; Promoter Regions, Genetic; Pyrazinamide; Republic of Korea; Rifampin; Sequence Analysis, DNA; Streptomycin; Tuberculosis, Multidrug-Resistant | 2013 |
Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required?
Topics: Adult; Amikacin; Antitubercular Agents; Audiology; Drug Monitoring; Female; Hearing Loss; Humans; Kidney; Male; Retrospective Studies; Tuberculosis, Multidrug-Resistant | 2013 |
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Sputum; Tanzania; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2014 |
Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; India; Kanamycin; Microbial Sensitivity Tests; Microscopy; Moldova; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Peru; Predictive Value of Tests; Reproducibility of Results; South Africa; Sputum; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2014 |
Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China.
Topics: Amikacin; Antitubercular Agents; Capreomycin; China; Drug Resistance, Multiple, Bacterial; Genotype; Humans; Kanamycin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Point Mutation; Tuberculosis, Multidrug-Resistant | 2014 |
Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss.
Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Drug Administration Schedule; Female; Hearing Loss; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Risk; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2014 |
Genotypic susceptibility testing of Mycobacterium tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid sloppy molecular beacon-based assay identifies more cases of low-level drug resistance than phenotypic Lowenstein-Jensen testin
Topics: Amikacin; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Genotyping Techniques; Humans; Kanamycin Resistance; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Reproducibility of Results; Sensitivity and Specificity; Sequence Analysis, DNA; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2015 |
Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis.
Topics: Amikacin; Antibiotics, Antitubercular; Capreomycin; Drug Resistance, Multiple, Bacterial; Humans; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2015 |
Combination of amikacin and doxycycline against multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Amikacin; Antitubercular Agents; Doxycycline; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pilot Projects; Tuberculosis, Multidrug-Resistant | 2015 |
Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
Topics: Adult; Aged; Amikacin; Antitubercular Agents; Base Sequence; Capreomycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Ethionamide; Female; Humans; Isoniazid; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Mycobacterium tuberculosis; Ofloxacin; Oxidoreductases; Rifampin; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant | 2016 |
Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis.
Topics: Adult; Amikacin; Antitubercular Agents; Biostatistics; Drug Monitoring; Female; Humans; Kanamycin; Male; Models, Statistical; Retrospective Studies; Specimen Handling; Tuberculosis, Multidrug-Resistant; Young Adult | 2015 |
Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients.
Topics: Adult; Amikacin; Antitubercular Agents; Area Under Curve; Audiometry; Clinical Decision-Making; Female; Hearing Loss, Sensorineural; Humans; Machine Learning; Male; Middle Aged; Probability; ROC Curve; Tuberculosis, Multidrug-Resistant | 2015 |
Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Body Weight; Chi-Square Distribution; Child; Child, Preschool; Coinfection; Hearing Loss; Hearing Tests; HIV Infections; Humans; Incidence; Infant; Infant, Newborn; Kanamycin; Logistic Models; Middle Aged; Namibia; Retrospective Studies; Risk Assessment; Risk Factors; Sex Factors; Tuberculosis, Multidrug-Resistant | 2015 |
Drug-resistant tuberculosis plagues India.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; India; Isoniazid; Kanamycin; Medication Adherence; Mycobacterium tuberculosis; Nonprescription Drugs; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables.
Topics: Acetyltransferases; Amikacin; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Capreomycin; Drug Resistance, Multiple, Bacterial; Genes, rRNA; Genotype; Humans; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Phenotype; Promoter Regions, Genetic; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant | 2016 |
Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Genotyping Techniques; Humans; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Sensitivity and Specificity; Tuberculosis, Multidrug-Resistant | 2016 |
Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China.
Topics: Amikacin; China; Extensively Drug-Resistant Tuberculosis; Humans; Kanamycin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Rifampin; Sensitivity and Specificity; Sputum; Tuberculosis, Multidrug-Resistant | 2016 |
Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
Topics: Adolescent; Adult; Aged; Amikacin; Antitubercular Agents; China; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium tuberculosis; Ofloxacin; Prospective Studies; Pyrazinamide; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2016 |
Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.
Topics: Amikacin; Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2016 |
Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Antitubercular Agents; Artificial Intelligence; Botswana; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Theoretical; Mycobacterium tuberculosis; Regression Analysis; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2016 |
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Clofazimine; Depression; Drug Costs; Emigrants and Immigrants; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Health Care Costs; Humans; India; Isoniazid; Linezolid; Male; Mediastinum; Microbial Sensitivity Tests; Moxifloxacin; New Zealand; Pyrazinamide; Radiography, Thoracic; Rifampin; Schizophrenia, Paranoid; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pleural; Tuberculosis, Pulmonary | 2016 |
Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; Drug Resistance, Multiple, Bacterial; France; Humans; Kanamycin; Mutation; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 2017 |
Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; Extensively Drug-Resistant Tuberculosis; Humans; Mutation; Mycobacterium tuberculosis; Ofloxacin; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant; Uzbekistan | 2009 |
Cross-resistance of Mycobacterium tuberculosis isolates among streptomycin, kanamycin and amikacin.
Topics: Amikacin; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Humans; Kanamycin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Streptomycin; Tuberculosis, Multidrug-Resistant | 2009 |
High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; Georgia (Republic); Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant | 2009 |
Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis.
Topics: Acetyltransferases; Amikacin; Anti-Bacterial Agents; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Humans; Kanamycin; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Promoter Regions, Genetic; Transcription, Genetic; Tuberculosis, Multidrug-Resistant | 2009 |
Amikacin-induced hypomagnesaemic tetany complicating multidrug-resistant tuberculosis treatment.
Topics: Adult; Amikacin; Antitubercular Agents; Drug Monitoring; Female; Humans; Hypokalemia; Magnesium; Magnesium Deficiency; Tetany; Tuberculosis, Multidrug-Resistant | 2010 |
Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Phenotype; Polymerase Chain Reaction; RNA, Ribosomal, 16S; Sequence Analysis, DNA; South Africa; Tuberculosis, Multidrug-Resistant | 2012 |
Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing.
Topics: Amikacin; Antitubercular Agents; Bacterial Typing Techniques; Base Sequence; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Genotype; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Mycobacterium tuberculosis; Ofloxacin; Phenotype; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Tuberculosis, Multidrug-Resistant | 2012 |
Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB.
Topics: Amikacin; Antitubercular Agents; Aza Compounds; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Quinolines; Rifampin; Statistics, Nonparametric; Tuberculosis, Multidrug-Resistant | 2012 |
Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Communicable Disease Control; Cycloserine; Directly Observed Therapy; Drug Combinations; Ethionamide; Hong Kong; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Population Surveillance; Program Evaluation; Recurrence; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2004 |
[A case of pulmonary multiresistant Mycobacterium bovis tuberculosis in Madagascar].
Topics: Amikacin; Antitubercular Agents; Capreomycin; Chronic Disease; Ciprofloxacin; Cough; DNA, Bacterial; Drug Therapy, Combination; Ethionamide; Humans; Kanamycin; Madagascar; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Mycobacterium bovis; Ofloxacin; Patient Compliance; Polymorphism, Restriction Fragment Length; Sputum; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2003 |
[Treatment and outcomes of tuberculosis with multidrug resistance of MBT in children and adolescents].
Topics: Adolescent; Amikacin; Antitubercular Agents; Child; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Isoniazid; Kanamycin; Male; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2007 |
The management of mycobacterial infections in HIV seropositive individuals. Jefferiss Wing Therapeutics and Protocols Group.
Topics: Adrenal Cortex Hormones; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Ciprofloxacin; Clarithromycin; Clofazimine; Drug Therapy, Combination; Ethambutol; HIV Infections; Humans; Isoniazid; Mycobacterium avium-intracellulare Infection; Mycobacterium Infections; Nontuberculous Mycobacteria; Practice Guidelines as Topic; Pyrazinamide; Pyridoxine; Radiography; Rifabutin; Rifampin; Tuberculosis, Meningeal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 1996 |
Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Drug Carriers; Drug Therapy, Combination; Humans; Liposomes; Male; Mycobacterium tuberculosis; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 1998 |
[Breast abscess and pregnancy toxemia revealing multidrug resistant tuberculosis].
Topics: Abscess; Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Breast Diseases; Bronchoscopy; Cesarean Section; Ciprofloxacin; Drug Therapy, Combination; Eclampsia; Ethambutol; Female; Follow-Up Studies; Humans; Infant, Newborn; Pregnancy; Pregnancy Complications, Infectious; Pyrazinamide; Radiography, Thoracic; Time Factors; Tomography, X-Ray Computed; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 1999 |
Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report.
Topics: Adult; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Drug Therapy, Combination; Humans; Injections, Spinal; Levofloxacin; Male; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Meningeal; Tuberculosis, Multidrug-Resistant | 2001 |
Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Audiometry; Child; Creatinine; Female; Hearing Loss, Bilateral; Humans; Kanamycin; Kidney; Kidney Diseases; Male; Middle Aged; Retrospective Studies; Streptomycin; Time Factors; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2002 |